NCT04970992View on ClinicalTrials.gov

A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 12, 2021

Primary Completion Date

November 7, 2024

Study Completion Date

April 1, 2025

Conditions
Solid TumorLymphoma
Interventions
DRUG

DZ-002

DZ-002 Injection

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Da Zen Theranostics Inc

INDUSTRY

NCT04970992 - A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma | Biotech Hunter | Biotech Hunter